

Ref. No: 192271219
From: Commercial
Date: 27/12/19
Subject: biologics and biosimilar prescribing in Rheumatology.

REQUEST

I have a Freedom of Information request regarding biologics and biosimilar prescribing in Rheumatology.

Could you please provide me with the following numbers of patients treated in the last 12 months with the following drugs.

- Abatacept [Orencia]
- Adalimumab [Amgevita]
- Adalimumab [Hulio]
- Adalimumab [Humira]
- Adalimumab [Hyrimoz]
- Adalimumab [Imraldi]
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Brodalumab [Kyntheum]
- Certolizumab [Cimzia]
- Dimethyl fumarate [Skilarence]
- Etanercept [Benepali]
- Etanercept [Enbrel]
- Etanercept [Erelzi]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Flixabi]
- Infliximab [Inflectra]
- Infliximab [Remicade]
- Infliximab [Remsima]
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab [Rixathon]
- Rituximab [Truxima]

- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tildrakizumab [Ilumetri]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

If you are unable to provide figures for the drugs listed above for prescribing within Rheumatology, then could you instead provide figures for the above but regardless of disease and indication please?

RESPONSE

Rheumatology patients issued with selected drugs 1st Jan 2019 – 31st Dec 2019:

Drug	Count of Patients
• Abatacept [Orencia]	42
• Adalimumab [Amgevita]	128
• Adalimumab [Hulio]	0
• Adalimumab [Humira]	123
• Adalimumab [Hyrimoz]	0
• Adalimumab [Imraldi]	0
• Apremilast [Otezla]	*
• Baricitinib [Olumiant]	49
• Brodalumab [Kyntheum]	0
• Certolizumab [Cimzia]	22
• Dimethyl fumarate [Skilarence]	0
• Etanercept [Benepali]	121
• Etanercept [Enbrel]	63
• Etanercept [Erelzi]	0
• Golimumab [Simponi]	38
• Guselkumab [Tremfya]	0
• Infliximab [Flixabi]	0
• Infliximab [Inflectra]	0
• Infliximab [Remicade]	*
• Infliximab [Remsima]	18
• Ixekizumab [Taltz]	0
• Risankizumab [Skyrizi]	0
• Rituximab [MabThera]	*
• Rituximab [Rixathon]	0
• Rituximab [Truxima]	62
• Sarilumab [Kevzara]	0
• Secukinumab [Cosentyx]	25
• Tildrakizumab [Ilumetri]	0
• Tocilizumab [Ro Actemra]	48
• Tofacitinib [Xeljanz]	0
• Upadacitinib [Rinvoq]	0
• Ustekinumab [Stelara]	6

*We are unable to provide the information you require as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under the Data Protection Act 1998. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the Act.